Blair William & CO Galectin Therapeutics Inc Transaction History
Blair William & CO
- $34.8 Billion
- Q2 2025
A detailed history of Blair William & CO transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Blair William & CO holds 37,884 shares of GALT stock, worth $142,822. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,884
Previous 37,884
-0.0%
Holding current value
$142,822
Previous $46,000
71.74%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding GALT
# of Institutions
88Shares Held
9.66MCall Options Held
587KPut Options Held
438K-
Vanguard Group Inc Valley Forge, PA2.18MShares$8.24 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$5.9 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.19MShares$4.49 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$2.51 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY480KShares$1.81 Million0.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $224M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...